US Edition
NMPA Accepted Essex's Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
HONG KONG, August 13, 2025 – (Asia Pacific Business News via SeaPRwire.com) – Essex Biotech Limited (“Essex Bio” or the “Group”, stock code: 1061.HK) is pleased to announce that the Group’s Market Registration Application (“BLA”) for the recombinant anti-VEGF intraocular injection EB12-20145P (HLX04-O) has recently been accepted by the Center for Drug Evaluation (“CDE”) of the China National Medical Products Administration (“NMPA”). This product…
HONG KONG, August 13, 2025 – (Asia Pacific Business News via SeaPRwire.com) – Essex Biotech Limited (“Essex Bio” or the “Group”, stock code: 1061.HK) is pleased to announce that the Group’s Market Registration Application (“BLA”) for the recombinant anti-VEGF intraocular injection EB12-20145P (HLX04-O) has recently been accepted by the Center for Drug Evaluation (“CDE”) of the China National Medical Products Administration (“NMPA”). This product…
NMPA Accepted Essex's Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration
HONG KONG, Aug 13, 2025 - (ACN Newswire) - Essex Bio-Technology Limited ("Essex" or the "Group", Stock Code: 1061.HK) is pleased to announce that a Biologics License Application ("BLA") for EB12-20145P (HLX04-O), a recombinant anti-VEGF humanized monoclonal antibody injection, has recently been accepted by the Centre for Drug Evaluation ("CDE") of the National Medical Products Administration ("NMPA") in China. The product is jointly developed by…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
